Notice of in-court restructuring proceedings of Orphazyme A/S
Mar 18, 2022
Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that following the Company’s filing of a petition for an in-court restructuring (in Danish rekonstruktion) of Orphazyme on March 10, 2022 (please see company announcement no. 10/2022), the Danish Maritime and Commercial High Court (the “Court”) has commenced the restructuring proceedings of the Company on March 11, 2022 at 7:00 am (CET). The Court has appointed attorney John Sommer Schmidt as restructuring administrator.
Notice of in court restructuring proceedings of Orphazyme
Read moreCommencement of in-court restructuring of Orphazyme A/S
Mar 10, 2022
Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that, following the receipt of the negative Trend Vote as announced on February 23, 2022 (please see company announcement no. 07/2022), and considering the Company’s financial position, the Board of Directors of the Company has today decided to file a petition for an in-court restructuring of Orphazyme. As a part of the restructuring efforts, the Company will also institute a reduction of approximately 50% of the Company’s current global workforce.
Commencement of in court restructuring of Orphazyme
Read moreUpdated Financial Calender for 2022
Mar 3, 2022
Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, today announced an update to the Financial Calendar for 2022. The planned date of the Annual General Meeting is changed to April 29, 2022, and the publication of the Annual Report for 2021 is changed to April 7, 2022.
Updated Financial Calender for 2022 1
Read moreAnders Vadsholt takes over as CEO of Orphazyme
Feb 28, 2022
Company announcement No. 08/2022 www. orphazyme. com Company Registration No. 32266355 Copenhagen, Denmark, February 28, 2022 – Orphazyme A/S (ORPHA.
Anders Vadsholt takes over as CEO of Orphazyme
Read moreOrphazyme announces update on regulatory review of arimoclomol in the European Union
Feb 23, 2022
Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, today announced an update on the ongoing review of the Marketing Authorisation Application (MAA) for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C (NPC) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Orphazyme announces update on regulatory review of arimoclomol in the European Union
Read moreCapital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program
Feb 18, 2022
Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, announces that the Company has issued new shares in the period from Friday, February 11, 2022 to Thursday, February 17, 2022 as a result of the utilization of the Company’s U.S. At-the-Market Offering Program with Cowen and Company, LLC (“Cowen”). On February 11, 2022, a total of 360,000 ordinary shares of nominally DKK 1 each, represented by American Depositary Shares (“ADSs”), have been issued by the Company and sold in the market by Cowen as the sales agent at market price as determined by the Company’s Board of Directors in accordance with the authorization in article 3.1 of the Company’s Articles of Association.
Read moreResolutions passed at the Extraordinary General Meeting
Feb 15, 2022
Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today held an Extraordinary General Meeting, at which the general meeting.
Resolutions passed at the Extraordinary General Meeting
Read moreAmendment of proposals put forward at the Extraordinary General Meeting
Feb 14, 2022
Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the Board of Directors has decided to limit the scope of the proposed authorizations set forward under items 1.2, 1.3 and 1.4 of the agenda of the Extraordinary General Meeting to be held tomorrow, February 15, 2022.
Amendment of proposals put forward at the Extraordinary General Meeting
Read moreOrphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States
Feb 11, 2022
Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today provides an update on the process and anticipated timelines for resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C (NPC).
Read moreOrphazyme to present additional data on arimoclomol’s mechanism of action during 2022 Annual WORLDSymposium™
Feb 7, 2022
Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced it will present new non-clinical data on its investigational drug arimoclomol during the 18th Annual WORLDSymposium™ Scientific Meeting, to be held in San Diego, CA and virtually on February 7-11, 2022.
Read more